SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-04706

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET		
		Day	Month	Year			Day	Month	Year
CFUC	NICARAGUA	02	Oct	2015	9	Female		Apr	2025

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty (Off label dosing (10074165), Off label use (10053762))
Unknown
2) Frequent headache (Headache (10019211), Headache (10019211))
(/Apr/2025 -) - Recovering/Resolving

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (22.5 milligram(s), 1 in 3 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Central Precocious Puberty [10073186 - Central precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
(14-Apr-2025 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CENTRAL PRECOCIOUS PUBERTY (10073186, Central precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1--9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-04706
24c. DATE RECEIVED BY MANUFACTURER: 14/Jul/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 18/Jul/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium via the ‘‘ASOFARMA A TU LADO'' Patient Support Program (reference number: NI-ADIUM-NI-0058-20250714) on 14-Jul-2025 from a consumer or other non-health professional regarding a child 09-year-female patient who experienced non-serious events of ''Frequent headache'' (headache) and ''Female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty'' (off label use) during Eligard (leuprorelin acetate) 22.5 mg therapy for central precocious puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 15-Jul-2025.

The patient's medical history was unknown and current condition included central precocious puberty.

Concomitant medication was unknown.

On 14-Apr-2025, the patient began receiving Eligard 22.5 mg every 3 months, via subcutaneous route, for central precocious puberty (Lot numbers and Expiration dates were not provided).

On an unknown date of Apr-2025, the patient had frequent headache.

Corrective treatment was unknown.

Action taken with Eligard in response to events was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of headache was recovering and off label use was unknown.

The reporter did not assess the seriousness of the events headache and off label use.

The reporter assessed the causality for headache as related and did not provide for off label use in relationship to Eligard and Eligard unspecified device.

The patient or family member or other non-health professional agrees to be contacted for future follow-ups and to contact their treating physician.

Listdenss
off label use >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
off label use> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
off label use> Eligard®>unlisted as per USPI Eligard®>Feb-2025
off label use> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

headache>Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
headache> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
headache> Eligard®>unlisted as per USPI Eligard®>Feb-2025
headache> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding a child 09-year-female patient who experienced headache (Frequent headache) and off label use (Female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty) during Eligard (leuprorelin acetate) 22.5 mg therapy for central precocious puberty. Tolmar assessed the reported event as non-serious since they did not meet the ICH seriousness criteria. The causality of event headache was assessed as related to drug component of Eligard(not related to device) considering the closed temporality. The causality of event off label use was assessed as not related to Eligard (drug and device) as it is due to human action/error as per the reported information.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	:	Eligard® (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
Lot Number	:	1) Unknown
Daily Dose	:	(22.5 milligram(s), 1 in 3 Month)
Route of Admin	:	1) Subcutaneous
Indications	:	1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug	:	Dose not changed

Continuation Sheet for CIOMS report

Causality

1) Female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty (Off label dosing - 10074165, Off label use - 10053762)

Causality as per reporter	: Not Reported
Causality as per Mfr	: Not Related
DeChallenge	: Not applicable
ReChallenge	: Not Applicable

2) Frequent headache (Headache - 10019211, Headache - 10019211)

Causality as per reporter	: Related
Causality as per Mfr	: Related
DeChallenge	: Not applicable
ReChallenge	: Not Applicable

Labeling :

1) Female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty
CORE UnLabeled

2) Frequent headache
CORE Labeled

2) Drug	: Eligard® Unspecified Device (Leuprolide acetate)
Active Substance	: 1) Leuprolide acetate
Drug Characterization	: Suspect
Form of Admin	: 1) Injection
Lot Number	: 1) Unknown
Route of Admin	: 1) Subcutaneous
Indications	: 1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug	: Not applicable

Causality

1) Female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty (Off label dosing - 10074165, Off label use - 10053762)

Causality as per reporter	: Not Reported
Causality as per Mfr	: Not Related
DeChallenge	: Not applicable
ReChallenge	: Not Applicable

2) Frequent headache (Headache - 10019211, Headache - 10019211)

Causality as per reporter	: Related
Causality as per Mfr	: Not Related
DeChallenge	: Not applicable
ReChallenge	: Not Applicable

Labeling :

1) Female patient being treated with the drug Eligard 22.5 mg for the indication Central Precocious Puberty
CORE

2) Frequent headache
CORE